ArchivesCategories |
Back to Blog
Prothrombin complex concentrate (PCC) is a hemostatic blood product that contains four vitamin K-dependent clotting factors (II, VII, IX, and X). It is used as an alternative to fresh frozen plasma for the reversal of oral anticoagulants (vitamin K antagonists or VKAs) in bleeding patients. Studies have indicated that prothrombin complex concentrates provide better reversal of warfarin than fresh frozen plasma in the treatment of patients with bleeding complications after surgery and for the management of massive perioperative coagulopathy. However, it also has some limitations such as thromboembolic events and the risk of viral or pathogen transmission.
The growing number of plasma collection centers in the region also plays a vital role in augmenting the Europe prothrombin complex concentrate market. A large number of these plasma centers offer safe and effective treatment for bleeding disorders. However, safety concerns related to thromboembolic events and disseminated intravascular coagulation (DIC) due to the application of prothrombin complex concentrates are some of the major factors hindering the adoption of this product. Prothrombin complex concentrate (PCC) is a type of plasma-derived medication that contains three or four blood clotting factors and may also contain factor VII. It is a popular choice for replacement therapy in hemophilia B patients who have a deficiency of blood clotting factors. In addition, it has also been found to reverse iatrogenic coagulopathy caused by oral anticoagulants in critically bleeding patients. Although a number of guidelines recommend prothrombin complex concentrates in these patients, few data are available regarding the efficacy and safety of this treatment. The present systematic review synthesizes evidence on the efficacy and safety of prothrombin complex concentrate to reverse coagulopathy in critically bleeding patients treated with oral anticoagulants. Prothrombin complex concentrate (PCC) is a blood product used for clotting purposes. It contains several blood clotting factors, including factors II, VII, IX, and X. The growing adoption of plasma-based therapies, a large patient pool with congenital factor IX deficiency, and the rising prevalence of hemophilia are the key driving factors for the growth of the PCC market. Based on the type, the prothrombin complex concentrate market is segmented into 3-factor and 4-factor prothrombin complex concentrates. It is also segmented based on application and end use. The rising prevalence of thrombotic disorders, technological advancements in the field of coagulation treatment, and favorable reimbursement scenarios are expected to drive the growth of this market. The prothrombin complex concentrate is a synthetic compound that contains the blood clotting factors II, IX, and X. It is used to treat hemophilia B, prevent bleeding, and treat other conditions. The prothrombin complex is also called the factor IX complex. It is a blood substitute for factor IX. However, it is not as effective as the natural product. Some versions also contain factor VII. In addition to being a better choice for patients with bleeding disorders, prothrombin complex concentrates are safer than fresh frozen plasma. While FFP was the preferred anticoagulant in many situations, its use was linked to increased risks of thromboembolic events. Those suffering from hepatitis or liver failure may benefit from prothrombin complex concentrate. It is a safe alternative to fresh frozen plasma and can reverse the effects of anticoagulants.
0 Comments
Read More
Leave a Reply. |